Sign in to view content

Phase 3 Randomized Studies of Efficacy and Safety of Revakinagene Taroretcel Producing Ciliary Neurotrophic Factor (CNTF) in Macular Telangiectasia Type 2

Emily Y. Chew, MD

Video
Published 2023

Related

Episode 6: YAG Vitreolysis for Symptomatic Floaters with Dr. Chirag Shah
Keyvan Koushan, MD, FRCSC
Member Podcasts
2018
Relationship Between Number of Intermediate-Large Drusen and Geographic Atrophy Lesion Growth Rate in the Sham Groups of the DERBY, OAKS, and FILLY Trials
Eleonora Lad, MD, PhD
Annual Meeting Talks
2022
Aflibercept 8 mg for Diabetic Macular Edema: 2-Year Results of the Phase 2/3 PHOTON Trial
Diana V Do, MD, FASRS
Annual Meeting Talks
2023

Category: Retinal Vascular Disease

See more